Your Guide to ARA-290 (Cibinetide): Benefits, Dosage, and More

Explore the benefits, uses, dosage, side effects, and research behind ARA-290 (Cibinetide). A concise guide for biohackers and health enthusiasts.

Track your Biohacking Protocols & Supplements with a Biohacking AI Coach Biohackr IOS app

Your Guide to ARA-290 (Cibinetide): Benefits, Dosage, and More

Looking to optimize your health or performance with ARA-290 (Cibinetide)? This guide breaks down everything you need to know about this popular therapeutic peptide, from its benefits and dosage to the latest research and biohacker insights.

What is ARA-290 (Cibinetide)?

ARA-290 (Cibinetide) is a synthetic peptide analogue derived from the innate repair receptor (IRR) binding domain of erythropoietin. It is being investigated for its potential tissue-protective and anti-inflammatory effects, particularly in conditions involving nerve damage.

Key Potential Benefits & Uses

Based on research, ARA-290 (Cibinetide) is being studied for:

  • Neuropathic Pain Reduction: Research indicates potential for reducing chronic neuropathic pain associated with various conditions.
  • Tissue Protection and Repair: Studies suggest it may promote tissue repair and reduce inflammation in damaged tissues, especially nerves.
  • Mechanism: Works by activating the innate repair receptor (IRR), which consists of the erythropoietin receptor (EpoR) and the beta common receptor (βcR).

Scientific Evidence: What Does the Research Say?

  • Clinical Trials: ARA-290 (Cibinetide) has been evaluated in clinical trials for conditions like neuropathic pain associated with sarcoidosis and fibromyalgia. Results have shown promise in some studies, demonstrating reduced pain and improved function.
  • Strength of Evidence: Emerging. Research is primarily in clinical trial phases, with results from specific populations demonstrating potential efficacy, but it is not yet a widely approved therapeutic.

How to Take ARA-290 (Cibinetide)

  • Common Forms: Primarily administered via subcutaneous injection in clinical trial settings.
  • Typical Dosage: Dosages are specific to clinical trial protocols and are not established for general use. Typical doses in trials are often calculated based on body weight or are fixed amounts, administered periodically (e.g., daily or multiple times per week). This is not a supplement; dosage should only be determined by medical professionals within clinical trial contexts.
  • Timing: Timing is determined by the clinical trial protocol.

Synergies & Stacking

  • ARA-290 (Cibinetide) is an investigational therapeutic peptide and is not commonly 'stacked' with dietary supplements in a biohacking context. Its use is confined to medical research settings.

Potential Side Effects & Precautions

Like any therapeutic agent, ARA-290 (Cibinetide) may cause side effects, though they are typically mild. These can include:

  • Injection Site Reactions: Redness, pain, or swelling at the injection site.
  • Headache: Reported in some clinical trial participants.
  • Precautions: ARA-290 (Cibinetide) is an investigational drug, not a dietary supplement. Its use should only occur under the strict supervision of a qualified healthcare professional within the context of a clinical trial. It is not available for purchase or self-administration outside of these regulated settings.

Choosing the Right Form & Quality

  • Quality Tips: As an investigational pharmaceutical product, ARA-290 (Cibinetide) is subject to rigorous manufacturing standards and quality control dictated by regulatory bodies for clinical trials. It is not available for purchase from supplement vendors.

Biohacker Insights & Community Experiences

  • Common Experiences: Due to its status as an investigational drug only available in clinical trials, widespread biohacker anecdotes or community experiences outside of research participants are limited or non-existent.

Frequently Asked Questions (FAQs)

  • Is ARA-290 (Cibinetide) available as a dietary supplement?
    • Answer: No, ARA-290 (Cibinetide) is an investigational therapeutic peptide and is only available for use within regulated clinical trials under medical supervision.
  • What types of conditions is ARA-290 (Cibinetide) being studied for?
    • Answer: Primarily for conditions involving chronic neuropathic pain and tissue damage, such as sarcoidosis-associated neuropathy and other inflammatory or degenerative conditions.

Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new supplement, especially if you have underlying health conditions or are taking medications.